Business
Syndax Announces Participation at Citi's Biopharma Virtual Co-Panel Day
WALTHAM, Mass., May 11, 2022 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical-stage biopharmaceutical
About this update from Syndax Pharmaceuticals, Inc.
[{"type":"text","content":"WALTHAM, Mass., May 11, 2022 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. (\"Syndax,\" the \"Company\" or \"we\") (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that Michael A. Metzger, Chief Executive Officer of Syndax, will participate in a panel discussion on targeted oncology at Citi's Biopharma Virtual Co-Panel Day on Wednesday, May 18, 2022 at 1:30 p.m. ET.\nA live webcast of the panel can be accessed from the Investor section of the Company's website at www.syndax.com, where a replay of the events will also be available for a limited time.\nAbout Syndax Pharmaceuticals, Inc. Syndax Pharmaceuticals is a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies. Highlights of the Company's pipeline include revumenib (SNDX-5613), a highly selective inhibitor of the Menin–MLL binding interaction, and axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1 (CSF-1) receptor, both currently in pivotal trials. For more information, please visit www.syndax.com or follow the Company on Twitter and LinkedIn.\nSyndax Contacts\nInvestor ContactMelissa ForstArgot [email protected] Tel 212.600.1902\nMedia ContactBenjamin [email protected] Tel 862.368.4464\nSNDX-G\n \n View original content:https://www.prnewswire.com/news-releases/syndax-announces-participation-at-citis-biopharma-virtual-co-panel-day-301544712.html\nSOURCE Syndax Pharmaceuticals, Inc.","length":3296,"tagName":"div"}]